Therapeutic Efficacy and Safety of Palonosetron in Treatment of Postoperative Nausea and Vomiting

PHASE3CompletedINTERVENTIONAL
Enrollment

384

Participants

Timeline

Start Date

January 31, 2012

Primary Completion Date

June 30, 2012

Study Completion Date

June 30, 2012

Conditions
Laparoscopic Gynecologic, Abdominal, Other SurgeryGeneral Anesthesia
Interventions
DRUG

Palonosetron

palonosetron 0.075 mg intravenous injection over 10 seconds when nausea with NRS \>= 4, or developement of retching or vomiting more than one time within three hour after the end of surgery.

DRUG

placebo control group

placebo intravenous injection over 10 seconds when nausea with NRS \>= 4, or developement of retching or vomiting more than one time within three hour after the end of surgery.

Trial Locations (4)

135-710

Samsung Medical Center, Seoul

Unknown

Bungdang Seoul National University Hospital, Seoul

Kangpook Samsung Hospital, Seoul

Sangye Bahk Hospital, Inje School of Medicine, Seoul

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

HK inno.N Corporation

INDUSTRY

lead

Samsung Medical Center

OTHER

NCT01568268 - Therapeutic Efficacy and Safety of Palonosetron in Treatment of Postoperative Nausea and Vomiting | Biotech Hunter | Biotech Hunter